Review Article
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond
| | Characteristics | | Timeframe | | | 2000–2004 | 2005–2009 | 2010–2014 | 2015–2019 |
| | Total studies | 199 | 42 | 42 | 54 | 61 | NA | | Total patients | 72934 | 16161 | 14054 | 23024 | 19695 | 0.45 | | Multicenter (%) | 167 (83.9) | 40 (95.2) | 41 (97.6) | 41 (75.9) | 45 (73.8) | 0.01 | | Phase III trials (%) | 104 (52.3) | 22 (52.4) | 26 (61.9) | 27 (50.0) | 29 (47.5) | 0.01 | | Topic | | | | | | 0.01 | | Surgery (%) | 12 (6.0) | 1 (2.4) | 3 (7.1) | 2 (3.7) | 6 (9.8) | | | Systemic therapy in the primary setting (%) | 94 (47.2) | 27 (64.3) | 26 (61.9) | 20 (37.0) | 21 (34.4) | | | Systemic therapy in the recurrent setting (%) | 93 (46.7) | 14 (33.3) | 13 (31.0) | 32 (59.3) | 34 (55.7) | | | Positive studies (%) | 72 (36.2) | 10 (23.8) | 13 (31.0) | 16 (29.6) | 33 (54.1) | 0.004 | | Histology or molecular biomarker selection criteria (%) | 15 (7.5) | 1 (2.4) | 1 (2.4) | 3 (5.6) | 10 (16.4) | 0.0001 | | Targeted therapy (%) | 62 (31.2) | 1 (2.4) | 1 (2.4) | 24 (44.4) | 36 (59.0) | 0.004 |
|
|
